Episode Details
Back to Episodes
Cannabis Stocks Navigate Volatility: Medical Growth and Beverage Breakthroughs Amid Regulatory Shifts
Published 2 months ago
Description
In the past 48 hours, the cannabis industry shows high trading activity in key stocks amid ongoing regulatory pressures and breakthrough partnerships, with no major market surges but persistent volatility.
Canopy Growth, Tilray Brands, and Aurora Cannabis topped dollar trading volumes on February 20 and 21, signaling investor focus on these leaders despite the Global Cannabis Stock Index dropping 10.6 percent in January and down 93.6 percent from its 2021 peak[1][3][5]. This continues a multi-year bear market driven by federal uncertainty in the US and Canada, where unpaid excise duties hit 269.8 million dollars by 2024 and Ottawa revoked over 4,100 licenses since legalization to curb black market diversion[7].
A landmark deal emerged February 22: Chicago's United Center, the largest US arena, partnered with RYTHM Inc. as its first official THC beverage sponsor, placing cannabis drinks alongside alcohol brands and highlighting cultural normalization[2]. This boosts the cannabis-infused drinks sector, now in over 3,000 US stores, though a looming November 2026 federal hemp-derived THC ban—with a 0.4mg per-container cap—threatens viability[2][6].
Leaders like Aurora Cannabis report record medical revenue, with over 80 percent of sales from high-margin global medical operations growing double-digits, pivoting from consumer markets[5]. Canopy Growth and Tilray emphasize scalable beverage lines[1][6]. No new product launches or emerging competitors surfaced in the last 48 hours, but upcoming events like Cannabis Europa Paris on February 19 underscore Europe's medical push, including France's shift to permanent access post-pilot[4].
Compared to prior weeks, stock watchlists remain static with no volume spikes, while the RYTHM deal marks a fresh mainstream win against regulatory headwinds. Consumer shifts favor beverages as alcohol alternatives, cutting intake nearly in half per studies, but supply chains face license cuts and debt[2][5][7]. Industry braces for US rescheduling clarity and tax reform wildcards in 2026[1][3][5]. (298 words)
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI
Canopy Growth, Tilray Brands, and Aurora Cannabis topped dollar trading volumes on February 20 and 21, signaling investor focus on these leaders despite the Global Cannabis Stock Index dropping 10.6 percent in January and down 93.6 percent from its 2021 peak[1][3][5]. This continues a multi-year bear market driven by federal uncertainty in the US and Canada, where unpaid excise duties hit 269.8 million dollars by 2024 and Ottawa revoked over 4,100 licenses since legalization to curb black market diversion[7].
A landmark deal emerged February 22: Chicago's United Center, the largest US arena, partnered with RYTHM Inc. as its first official THC beverage sponsor, placing cannabis drinks alongside alcohol brands and highlighting cultural normalization[2]. This boosts the cannabis-infused drinks sector, now in over 3,000 US stores, though a looming November 2026 federal hemp-derived THC ban—with a 0.4mg per-container cap—threatens viability[2][6].
Leaders like Aurora Cannabis report record medical revenue, with over 80 percent of sales from high-margin global medical operations growing double-digits, pivoting from consumer markets[5]. Canopy Growth and Tilray emphasize scalable beverage lines[1][6]. No new product launches or emerging competitors surfaced in the last 48 hours, but upcoming events like Cannabis Europa Paris on February 19 underscore Europe's medical push, including France's shift to permanent access post-pilot[4].
Compared to prior weeks, stock watchlists remain static with no volume spikes, while the RYTHM deal marks a fresh mainstream win against regulatory headwinds. Consumer shifts favor beverages as alcohol alternatives, cutting intake nearly in half per studies, but supply chains face license cuts and debt[2][5][7]. Industry braces for US rescheduling clarity and tax reform wildcards in 2026[1][3][5]. (298 words)
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI